[go: up one dir, main page]

EA200200348A1 - Фармацевтические растворы левосимендана - Google Patents

Фармацевтические растворы левосимендана

Info

Publication number
EA200200348A1
EA200200348A1 EA200200348A EA200200348A EA200200348A1 EA 200200348 A1 EA200200348 A1 EA 200200348A1 EA 200200348 A EA200200348 A EA 200200348A EA 200200348 A EA200200348 A EA 200200348A EA 200200348 A1 EA200200348 A1 EA 200200348A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical
levosimendana
mortars
injections
solutions
Prior art date
Application number
EA200200348A
Other languages
English (en)
Other versions
EA005067B1 (ru
Inventor
Реййо Бякстрем
Пяйви Гранвик
Ритва Хайкала
Сирпа Пельттари
Эва Саукко
Рейя Ирьеля
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8555263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200200348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA200200348A1 publication Critical patent/EA200200348A1/ru
Publication of EA005067B1 publication Critical patent/EA005067B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к растворам левосимендана для фармацевтического применения, и в частности для внутривенного введения. Растворы в соответствии с данным изобретением имеют повышенную стабильность и особенно применимы в качестве растворов для вливаний или инъекций либо концентратов для вливаний. Левосимендан полезен при лечении застойной сердечной недостаточности.Отчет о международном поиске был опубликован 2001.11.15.
EA200200348A 1999-09-10 2000-09-08 Фармацевтические растворы левосимендана EA005067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991925A FI109659B (fi) 1999-09-10 1999-09-10 Levosimendaanin farmaseuttisia liuoksia
PCT/FI2000/000761 WO2001019334A2 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan

Publications (2)

Publication Number Publication Date
EA200200348A1 true EA200200348A1 (ru) 2002-08-29
EA005067B1 EA005067B1 (ru) 2004-10-28

Family

ID=8555263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200348A EA005067B1 (ru) 1999-09-10 2000-09-08 Фармацевтические растворы левосимендана

Country Status (39)

Country Link
US (2) US6730673B1 (ru)
EP (1) EP1210085B1 (ru)
JP (1) JP4708648B2 (ru)
KR (1) KR100869752B1 (ru)
CN (1) CN1203855C (ru)
AR (1) AR025449A1 (ru)
AT (1) ATE315937T1 (ru)
AU (1) AU771027B2 (ru)
BG (1) BG65827B1 (ru)
BR (1) BRPI0013924B8 (ru)
CA (1) CA2382013C (ru)
CO (1) CO5180582A1 (ru)
CZ (1) CZ303095B6 (ru)
DE (1) DE60025627T2 (ru)
DK (1) DK1210085T3 (ru)
EA (1) EA005067B1 (ru)
EE (1) EE05375B1 (ru)
ES (1) ES2256034T3 (ru)
FI (1) FI109659B (ru)
HK (1) HK1049282B (ru)
HR (1) HRP20020298B1 (ru)
HU (1) HU228340B1 (ru)
IL (2) IL148379A0 (ru)
IS (1) IS2244B (ru)
ME (1) ME00523B (ru)
MX (1) MXPA02002423A (ru)
MY (1) MY125984A (ru)
NO (1) NO331989B1 (ru)
NZ (1) NZ517605A (ru)
PL (1) PL202356B1 (ru)
PT (1) PT1210085E (ru)
RS (1) RS50445B (ru)
SI (1) SI1210085T1 (ru)
SK (1) SK287154B6 (ru)
TR (1) TR200200620T2 (ru)
TW (1) TWI242434B (ru)
UA (1) UA73954C2 (ru)
WO (1) WO2001019334A2 (ru)
ZA (1) ZA200201828B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
CN100367964C (zh) * 2004-04-29 2008-02-13 王思清 左西孟旦-β环糊精包含物制剂
US20070032557A1 (en) * 2005-02-18 2007-02-08 Matti Kivikko Method for administering levosimendan
WO2008082871A1 (en) * 2006-12-28 2008-07-10 Orion Corporation Formulations of levosimendan for parenteral administration
US10046081B2 (en) 2008-04-11 2018-08-14 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. Electrospun dextran fibers and devices formed therefrom
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
US8697118B2 (en) * 2011-10-18 2014-04-15 St. Teresa Medical, Inc. Stabilizers for hemostatic products
CA2873502C (en) * 2012-05-18 2017-09-12 Luoda Pharma Pty Ltd Liquid formulation
CN105106113B (zh) * 2015-09-30 2019-07-26 济南康和医药科技有限公司 一种左西孟旦注射液及其制备方法
ES2782106T3 (es) * 2015-11-06 2020-09-10 Carinopharm Gmbh Formulaciones mejoradas de levosimendán para administración intravenosa como infusión o inyección y como concentrado de infusión
AU2016351557A1 (en) 2015-11-12 2018-05-31 St. Teresa Medical, Inc. A method of sealing a durotomy
CN108261398A (zh) * 2016-12-30 2018-07-10 齐鲁制药有限公司 一种含有左西孟旦的供注射用药物制剂及其制备方法
US10953128B2 (en) 2017-11-02 2021-03-23 St. Teresa Medical, Inc. Fibrin sealant products
CN111474289A (zh) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics, Inc. LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
CN111514147B (zh) * 2020-05-12 2021-09-17 成都欣捷高新技术开发股份有限公司 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法
US11760730B2 (en) * 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan
WO2023027670A2 (en) * 2021-08-23 2023-03-02 Tum Ekip Ilac Anonim Sirketi Lyophilized levosimendan compositions
CN115518037A (zh) * 2022-10-14 2022-12-27 上药东英（江苏）药业有限公司 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法
CN116473930B (zh) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 一种注射用左西孟旦及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia

Also Published As

Publication number Publication date
WO2001019334A2 (en) 2001-03-22
EP1210085A2 (en) 2002-06-05
KR20020048400A (ko) 2002-06-22
US6943164B2 (en) 2005-09-13
JP4708648B2 (ja) 2011-06-22
FI109659B (fi) 2002-09-30
US6730673B1 (en) 2004-05-04
CO5180582A1 (es) 2002-07-30
IS6296A (is) 2002-03-06
MXPA02002423A (es) 2002-08-12
EE05375B1 (et) 2011-02-15
SI1210085T1 (sl) 2006-04-30
ES2256034T3 (es) 2006-07-16
CA2382013C (en) 2009-08-11
MY125984A (en) 2006-09-29
IL148379A (en) 2006-12-10
HRP20020298A2 (en) 2003-06-30
TR200200620T2 (tr) 2002-09-23
BR0013924A (pt) 2002-05-21
BRPI0013924B8 (pt) 2021-05-25
AU7004400A (en) 2001-04-17
EA005067B1 (ru) 2004-10-28
HK1049282A1 (en) 2003-05-09
BG106589A (bg) 2002-11-29
CN1203855C (zh) 2005-06-01
HUP0202749A2 (hu) 2003-02-28
EE200200129A (et) 2003-04-15
EP1210085B1 (en) 2006-01-18
HK1049282B (zh) 2005-12-30
ZA200201828B (en) 2003-08-27
AR025449A1 (es) 2002-11-27
NO20021090D0 (no) 2002-03-05
HUP0202749A3 (en) 2003-03-28
YU16902A (sh) 2004-09-03
PT1210085E (pt) 2006-05-31
IS2244B (is) 2007-05-15
UA73954C2 (ru) 2005-10-17
AU771027B2 (en) 2004-03-11
HRP20020298B1 (hr) 2007-02-28
CA2382013A1 (en) 2001-03-22
FI19991925L (fi) 2001-03-10
TWI242434B (en) 2005-11-01
NO20021090L (no) 2002-03-05
PL354028A1 (pl) 2003-12-15
DK1210085T3 (da) 2006-05-08
RS50445B (sr) 2010-03-02
BR0013924B1 (pt) 2013-09-24
US20040106617A1 (en) 2004-06-03
WO2001019334A3 (en) 2001-11-15
HU228340B1 (en) 2013-03-28
CZ303095B6 (cs) 2012-03-28
BG65827B1 (bg) 2010-02-26
ME00523B (me) 2011-10-10
NO331989B1 (no) 2012-05-21
ATE315937T1 (de) 2006-02-15
NZ517605A (en) 2003-08-29
DE60025627D1 (de) 2006-04-06
CZ2002788A3 (cs) 2002-11-13
DE60025627T2 (de) 2006-11-16
KR100869752B1 (ko) 2008-11-21
JP2003509351A (ja) 2003-03-11
CN1373665A (zh) 2002-10-09
IL148379A0 (en) 2002-09-12
SK287154B6 (sk) 2010-01-07
PL202356B1 (pl) 2009-06-30
SK3272002A3 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
EA200200348A1 (ru) Фармацевтические растворы левосимендана
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
EA199901031A1 (ru) Производные бензимидазола
WO2000058293A3 (en) Glucokinase activators
EA200301222A1 (ru) Легочное введение химически модифицированного инсулина
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
EA200200502A1 (ru) Способ введения ингибитора фосфодиэстеразы 4
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
BR9713253A (pt) Derivados de 3-carboxamida de 5h-pirrol [2,1-c][1,4]-benzodiazepinas
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
ATE59781T1 (de) Potenzierung von prazosin.
MD990258A (en) Method of treatment of the acute viral hepatitis B
EA200001097A1 (ru) Стабильные композиции, содержащие левозимендан и альгиновую кислоту
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
DE60204967D1 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
EA200200234A1 (ru) Препараты для парентерального применения эстрамустин фосфата и альбумина
EA200100151A1 (ru) Производные пиперазинона и их применение
SE9003181D0 (sv) Use of heparin fraction
MY125300A (en) Synergistic combination for treatment of viral-mediated diseases
ATE127839T1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
EA200300725A1 (ru) Соединение азола в качестве противогрибковых средств
ATE69609T1 (de) Cardiotonische imidazolylphenylpyrrol-2-one.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): BY RU